Meet P3T

Pioneering
First-in-Class Therapies for Immune Disorders

A groundbreaking investment opportunity in preclinical-stage disease modifying drug development

Proof-of-Concept Results: TTA Activation by Phytochemicals
In Silico
In Vitro
In Vivo

In silico

In vitro

In vivo

Our misson is to develop novel anti-inflammatory, disease-modifying new chemical entities (NCEs) to address unmet needs in treating Spondyloarthritis (SpA).

Triple Target Activation

P3T’s proprietary NCE technology activates three anti-inflammatory targets, providing a revolutionary treatment for chronic immune-mediated inflammatory disorders like Spondyloarthritis (SpA).

View More

AI-Assisted Drug Design

Leveraging AI-driven “scaffold hopping” and generative AI for lead optimization, our solution targets unmet needs, improving on the traditional single-target drug paradigm.

View more

Organ-on-Chip Development

Our in-house platform enables biomarker-driven preclinical and clinical trials, ensuring the development of highly effective, first-in-class NCEs for SpA and related diseases.

view more
Problem & Solution

Chronic immune-mediated inflammatory disorders (IMIDs) are among the leading global health threats, second only to cardiovascular diseases like stroke and heart attacks.

In conditions such as Spondyloarthritis (SpA), chronic inflammation is often driven by a compromised gut barrier—commonly referred to as "leaky gut"—and dysbiosis, an imbalance in gut bacteria. These underlying issues lead to persistent inflammation, worsening disease symptoms, and a lack of effective long-term treatments.

Targeted Drug Delivery with Triple Target Activation (TTA)

Our approach combines precise drug delivery systems with Triple Target Activation (TTA) technology, simultaneously activating three key anti-inflammatory pathways. This innovative mechanism ensures maximum therapeutic effect, tackling chronic inflammation at its core and offering a significant advantage over traditional single-target treatments.

First-in-Class Disease-Modifying NCEs

P3T develops new chemical entities (NCEs) specifically designed to target secondary pathways involved in "leaky gut" and other underlying factors of Spondyloarthritis (SpA) and related diseases. These first-in-class, disease-modifying treatments aim to address critical unmet medical needs by providing long-lasting relief and improving patient outcomes.

Biomarker-Driven Development with Organ-on-Chip Technology:

P3T’s biomarker-driven preclinical and clinical development process utilizes cutting-edge "Organ-on-Chip" technology. This platform simulates human tissue behavior, allowing for highly accurate testing of our NCEs and optimizing treatment strategies for better efficacy and safety across different stages of drug development.

BUSINESS MODEL 01

Collaborative Development or Out-Licensing:

P3T offers collaboration and licensing opportunities to accelerate drug development, expand pipelines, and bring innovative therapies for immune-mediated inflammatory disorders to market faster.

BUSINESS MODEL 02

In-House Drug Development

Our in-house team drives drug discovery, optimizing NCEs, using AI-driven design, and conducting preclinical testing to ensure safety and efficacy.

BUSINESS MODEL 03

Compound and Biomarker Licensing

We provide licensing for novel compounds and biomarker technologies targeting immune-mediated diseases, offering partners access to groundbreaking innovations for their pipelines.

Unlocking a High-Growth Opportunity in Precision Medicine

Large and Growing Market Opportunity

The global SpA market is projected to grow from $5.32 billion in 2023 to $8.79 billion by 2030, with over 50 million affected worldwide. P3T’s solutions target this rapidly expanding market.

Differentiated, First-in-Class Technology

P3T’s Triple Target Activation (TTA) offers a novel, disease-modifying approach by targeting three pathways, addressing "leaky gut" and inflammation, validated through preclinical studies.

High Growth Potential with Minimal Initial Investment

P3T provides high-return potential with low initial investment, offering multiple pathways for commercialization through collaborative development, out-licensing, and biomarker licensing.

Possible Indications
Miroslav Harjaček
Founder and executive chairman
Inflammatory Bowel Disease
New treatments targeting inflammation in Crohn's and colitis.
Rheumatoid Arthritis
Modulating immune response to reduce joint inflammation.
InflammAGING
Addressing age-related inflammation for improved health.
Cellulite
Innovative therapies reducing inflammation behind cellulite.

Frequently Asked Questions

What is the core innovation behind P3T’s technology?
What stage of development is P3T in, and what are the upcoming milestones?
How large is the market opportunity for P3T’s NCEs?
What makes P3T’s technology different from existing treatments?
What kind of investment opportunities are available?

Made by the best minds in the industry.

Founder and Executive Chairman

Miroslav Harjaček

MD PhD, Professor of Pediatrics Serial entrepreneur and author of many scientific projects with more than 30 years of experience as Precticing Pediatric Rheumatologist.
Cofounder and CEO

Dario Naletilic

MD and business consultant
Big Pharma executive with more than 30 years of experience HC management instructor.
Cofounder and CSO

Zoran Gatalica

2% of the world best scientist with more than 35 years of experience in laboratory science.
Former Exc. Medical Director of Caris Life Sciences, Phoenix, AZ.
Extensive experience in development of clinical disease biomarkers
Cofounder and CMO

Nenad Sarapa

Clinical Development Consultant Former SVP of Clinical Development at OnCusp Therapeutics with 29 years of global pharmaceutical R&D experience.

Ready to invest?

Contact US

Feel free to send us an email and we will get back to you in the shortest possible time!

Sections
Company info
info@p3therapeutics.eu
P 3 Therapeutics d.o.o.
Balokovićeva ulica 51
10000 Zagreb, Croatia
OIB: 63459594863
Made by Clarico.